Genomic sequencing of a patient’s tumor and germline DNA can directly shape treatment choices by revealing actionable mutations, predicting response to therapies, and identifying inherited cancer risks. Clinical use of this information rests on robust evidence that specific genetic changes drive tumor growth and that drugs targeting those changes produce clinical benefit. Thomas J. Lynch at Dana-Farber Cancer Institute reported activating EGFR mutations that predict sensitivity to EGFR inhibitors in non–small-cell lung cancer, a discovery that established a model for linking genotype to therapy. Ahmet Zehir at Memorial Sloan Kettering described how broad genomic profiling uncovers clinically relevant alterations across tumor types, supporting routine sequencing in many advanced cancers.
How genetic profiling influences therapy selection
When a tumor carries a driver mutation such as EGFR, ALK, or BRAF, clinicians can often choose a targeted agent with higher expected benefit and different toxicity than standard chemotherapy. Genomic tests also report biomarkers that inform immunotherapy use: tumors with high tumor mutational burden or mismatch repair deficiency are more likely to respond to immune checkpoint inhibitors. These associations are probabilistic, not absolute—some patients with the biomarker do not respond, and some without it do. Sequencing results therefore modify but rarely determine decisions in isolation; they combine with clinical factors such as performance status and comorbidities.
Monitoring, resistance, and adapting therapy
Cancer genomes evolve under treatment pressure. Liquid biopsy methods for circulating tumor DNA, advanced by researchers including Bert Vogelstein at Johns Hopkins, enable noninvasive monitoring of emerging resistance mutations and minimal residual disease. Detecting resistance mechanisms early allows a shift to alternative targeted agents, combination therapies, or enrollment in clinical trials. However, the clinical utility of routine serial sequencing varies by tumor type and setting, and interpretation requires multidisciplinary input from oncologists, molecular pathologists, and genetic counselors.
Genomic findings also carry consequences beyond immediate drug choice. Identification of a germline pathogenic variant affects family members and brings preventive options into consideration. At the population level, disparities in access to genomic testing and targeted drugs can widen outcome gaps between regions and socioeconomic groups, making equitable implementation a policy as well as clinical challenge.
Evidence synthesizing genomic-guided care underpins guideline recommendations from major cancer organizations and has shifted standard practice for many cancers. Nonetheless, limitations remain: many tumors lack currently actionable alterations, functional significance of some variants is uncertain, and insurance coverage for testing and targeted agents differs across territories. Clinicians must weigh genomic data against clinical evidence and patient preferences.
Integrating personalized genomics into cancer care improves the precision of treatment selection, enables dynamic management of resistance, and identifies hereditary risks that impact families. Its effectiveness depends on validated biomarker–therapy relationships, rigorous interpretation by expert teams, and equitable access so benefits extend across cultural and territorial boundaries.